From the Research
Corynebacterium striatum urinary tract infections (UTIs) are typically treated with vancomycin as the first-line option due to increasing antibiotic resistance, as evidenced by a systematic review published in 2021 1. For uncomplicated cases, vancomycin is often administered at 15-20 mg/kg IV every 8-12 hours for 7-14 days, with dose adjustments based on renal function and therapeutic drug monitoring. Some key points to consider in the treatment of C. striatum UTIs include:
- High resistance to commonly used antibiotics like penicillins, cephalosporins, and fluoroquinolones, making susceptibility testing crucial before initiating therapy 1.
- The importance of removing any urinary catheters when possible, adequate hydration, and follow-up urine cultures to confirm eradication.
- Consultation with an infectious disease specialist may be beneficial for complicated cases or in patients with multiple comorbidities.
- C. striatum has been increasingly recognized as a significant pathogen in UTIs, particularly in patients with indwelling catheters, immunosuppression, or recent antibiotic exposure 2, 3.
- The use of vancomycin, linezolid, or daptomycin as alternative treatment options, with vancomycin being the preferred choice due to its high efficacy and low resistance rates 1.